Lyrica No More Effective Than Placebo Painkillers

Pfizer announced that the Lyrica drug, used to treat fibromyalgia and chronic pain disorders, is not effective in reducing neuropathic pain caused by HIV infection or diabetes, according to American News Report.

Pfizer ordered a halt to two phase III studies after a preliminary analysis showed that pregabalin, sold under the brand name Lyrica, was no more effective than a placebo.

In both studies — an HIV neuropathy study and a peripheral diabetic neuropathy study — patients were given Lyrica for six weeks and then switched to either a placebo or continued using Lyrica for 13 weeks. Pfizer said that patients who took Lyrica continued to show improvements, but they were not significantly different from those seen in the placebo group.

Related Articles on Pain Management:

Patients With Celiac Disease More Likely to Suffer Migraines
Pregabalin Bridges Gap in Treating Spinal Cord Injury Pain
Study Examines Why Vioxx Damaged Patients' Hearts

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast